For these studies, we used mice bearing Pten+/−Eμ-Myc lymphomas since mTOR is activated in these tumors and they respond to the combination of Dxr and Rap treatment [16], as well as to combinations of Dxr and the translation initiation inhibitor, silvestrol [17]. The gene discussed is MYC; the disease is lymphoma.